| Literature DB >> 25900078 |
Laurie M Baker1, Robert H Paul, Jodi M Heaps-Woodruff, Jee Yoon Chang, Mario Ortega, Zachary Margolin, Christina Usher, Brian Basco, Sarah Cooley, Beau M Ances.
Abstract
The incidence of HIV-associated dementia has been greatly reduced in the era of highly active antiretroviral therapy (HAART); however milder forms of cognitive impairment persist. It remains uncertain whether HAART regimens with a high degree of central nervous system penetration effectiveness (CPE) exert beneficial neurological outcomes in HIV-infected (HIV+) individuals on stable treatment. Sixty-four HIV-infected adults on HAART were assigned a CPE score using a published ranking system and divided into high (≥7; n = 35) and low (<7; n = 29) CPE groups. All participants completed neuropsychological testing in addition to structural neuroimaging. Neuropsychological tests included measures known to be sensitive to HIV with values converted into standardized scores (NPZ-4) based on published normative scores. A semi-automated methodology was utilized to assess brain volumetrics within cortical (grey and white matter) and subcortical (thalamus, caudate, putamen) regions of interest. Analyses assessed NPZ-4 and brain volumetric differences between HIV+ individuals with high and low CPE scores. No significant differences in brain integrity were observed between the two groups. Long-term HAART regimens with a high degree of CPE were not associated with significantly improved neuropsychological or neuroimaging outcomes in HIV+ adults. Results suggest that alternate mechanisms may potentially contribute to better neurological outcomes in the era of HAART.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25900078 PMCID: PMC4546556 DOI: 10.1007/s11481-015-9610-4
Source DB: PubMed Journal: J Neuroimmune Pharmacol ISSN: 1557-1890 Impact factor: 4.147